Effect of intranasal histamine on nasal mucosal blood flow and the antidiuretic activity of desmopressin.

Olanoff, Lawrence S.; Titus, Christina; Shea, Moira; Gibson, Raymond E.; Brooks, Carter D.

doi:10.1172/jci113148

Cited by 39 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The majority have used some type of fixation to the head of the patient, as a head-band [3,[7][8][9][10] or a bicycle helmet [11], Druceet al [6] used audio headphones with a clamp attached for the probe. Olanoff et al [12] used eith er an earphone headset or a chin rest with an adjustable clamp for the probe. Rangi et al [13] used an adjustable metal bar and a nasal cannula.…”

Section: Discussionmentioning

confidence: 99%

The Impact of the Measuring Distance on Laser-Doppler Measurements of the Micro-circulation in Human Nasal Mucosa

Grudemo

Juto²

1997

ORL

View full text Add to dashboard Cite

Fourteen healthy volunteers were examined using rhinostereometry (RSM) and micromanipulator-guided laser-Doppler flowmetry (LDF) on the inferior turbinate and nasal septum. There were significant differences of the flowmetry readings at different distances from the mucosal surface within 0–1.0 mm. Changes in LDF values due to a change in distance between probe and mucosa seem to be an important artefact that will influence the flowmetry, especially if the probe is fixed to the framework of the nose (i.e. the skull) and if the congestive status of the mucosa changes. This can be a problem especially during intranasal challenges with substances that influence congestion. These artefacts can be eliminated by using an RSM-guided micromanipulator that allows the probe to follow changes in congestion.

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of the Measuring Distance on Laser-Doppler Measurements of the Micro-circulation in Human Nasal Mucosa

Grudemo

Juto²

1997

ORL

View full text Add to dashboard Cite

show abstract

“…These are similar to the changes that occur in the common cold and hay fever, the relationship of which to nasal absorption is uncertain. Larsen et al (1987) reported that histamine-induced rhinitis did not influence nasal absorption of buserelin, whereas Olanoff et al (1987) reported that the nasal absorption of desmopressin was improved after a similar treatment.…”

Section: Safety Considerationsmentioning

confidence: 99%

The biopharmaceutical aspects of nasal mucoadhesive drug delivery

Ugwoke

Verbeke

Kinget

2001

Journal of Pharmacy and Pharmacology

295

158

View full text Add to dashboard Cite

Nasal drug administration has frequently been proposed as the most feasible alternative to parenteral injections. This is due to the high permeability of the nasal epithelium, allowing a higher molecular mass cut-off at approximately 1000 Da, and the rapid drug absorption rate with plasma drug profiles sometimes almost identical to those from intravenous injections.Despite the potential of nasal drug delivery, it has a number of limitations. In this review, the anatomy and physiology of the nasal cavity, as well as ciliary beating and mucociliary clearance as they relate to nasal drug absorption, are introduced. The rationale for nasal drug delivery and its limitations, some factors that influence nasal drug absorption, and the experimental models used in nasal drug delivery research are also reviewed. Nasal mucoadhesion as a promising method of nasal absorption enhancement is discussed, and factors that influence mucoadhesion, as well as safety of nasal mucoadhesive drug delivery systems are reviewed in detail.Nasal drug administration is presently mostly used for local therapies within the nasal cavity.

show abstract

“…Vasoconstrictors have frequently been used in combination with other drugs in nasal formulations to prevent adverse systemic effects by reducing systemic absorption (Urtti and Kyyrönen, 1989;Kyyrönen and Urtti, 1990a,b;Luo et al, 1991;Jä rvinen and Urtti, 1992) or to prolong the duration of action by reducing clearance from the delivery site (Adams et al, 1976;Liu et al, 1995). Vasodilators have also been used to enhance systemic bioavailability of drugs (Olanoff et al, 1987;Urtti and Kyyrönen, 1989). We hypothesized that reduced systemic absorption with a vasoconstrictor would increase residence time and increase deposition in the nasal epithelium.…”

mentioning

confidence: 99%

Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System

Dhuria

Hanson²,

Frey³

2008

J Pharmacol Exp Ther

View full text Add to dashboard Cite

The intranasal route of drug administration is noninvasive, convenient, and rapidly targets therapeutics to the central nervous system (CNS) using olfactory and trigeminal neural pathways connecting the nasal passages to the brain. The purpose of this research was to enhance intranasal drug targeting to the CNS by incorporating a vasoconstrictor [phenylephrine (PHE)] into nasal formulations containing therapeutic neuropeptides [hypocretin-1 (HC) or the dipeptide L-Tyr-D-Arg (D-KTP)]. Concentrations in CNS tissues, peripheral tissues, and blood were determined at 30 min following intravenous or intranasal administration of 125 I-labeled neuropeptides with and without PHE. Compared with intranasal controls, inclusion of 1% PHE in nasal formulations significantly reduced absorption into the blood for HC (65% reduction) and D-KTP (56% reduction), whereas it significantly increased deposition into the olfactory epithelium by ϳ3-fold for both. PHE (1%) significantly increased delivery to the olfactory bulbs for HC (2.1-fold) and D-KTP (3.0-fold), whereas it significantly reduced concentrations in the trigeminal nerve for HC (65% reduction) and D-KTP (39% reduction) and in most remaining brain regions by ϳ50% for both. The dramatic reduction in blood concentrations with PHE contributed to brain-to-blood concentration ratios that were significantly increased for HC throughout the brain (1.6 -6.8-fold) compared with intranasal controls. For D-KTP, 1% PHE significantly increased ratios only in the olfactory bulbs (5.3-fold). With a 5% PHE formulation, D-KTP ratios were significantly increased to additional brain areas (1.5-16-fold). Vasoconstrictor nasal formulations may have particular relevance for CNS therapeutics with adverse side effects where it would be advantageous to limit systemic exposure.It has been reported that greater than 98% of small-molecule and nearly 100% of large-molecule central nervous system (CNS) drugs developed by the pharmaceutical industry do not cross the blood-brain barrier (Pardridge, 2005). Intracerebroventricular or intraparenchymal drug administration can directly deliver therapeutics to the brain; however, these methods are invasive, inconvenient, and impractical for the numbers of individuals requiring therapeutic interventions for treating CNS disorders. Intranasal drug administration is a noninvasive and convenient means to rapidly target therapeutics of varying physical and chemical properties to the CNS. Although the exact mechanisms underlying intranasal delivery to the CNS are not well understood, the olfactory and trigeminal neural pathways connecting the nasal passages to the CNS are clearly involved (Thorne et al

show abstract

Effect of intranasal histamine on nasal mucosal blood flow and the antidiuretic activity of desmopressin.

Cited by 39 publications

References 21 publications

The Impact of the Measuring Distance on Laser-Doppler Measurements of the Micro-circulation in Human Nasal Mucosa

The Impact of the Measuring Distance on Laser-Doppler Measurements of the Micro-circulation in Human Nasal Mucosa

The biopharmaceutical aspects of nasal mucoadhesive drug delivery

Novel Vasoconstrictor Formulation to Enhance Intranasal Targeting of Neuropeptide Therapeutics to the Central Nervous System

Contact Info

Product

Resources

About